Biosimilar Market in Europe Overview 2018, Demand by Regions, Share, Trends, Growth and Forecast to 2023

1. Biosimilar Market in Europe Driven by Ongoing Awareness Initiatives Copyright © IMARC. All Rights Reserved

2. About IMARC Group Report Description IMARC is a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3. Report Description and Highlights Report Description Biosimilar Market in Europe Driven by Ongoing Awareness Initiatives Owing to the changing perception towards biosimilars and favorable guidelines laid down by the European Medicines Agency (EMA), the biosimilar market in Europe has witnessed a robust growth over the past several years. IMARC Group’s latest report, entitled “Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023”, finds that the biosimilar marketin Europe reached a value of US$ 2,013 Million in 2017. Biosimilars refer to biological drugs which are highly similar to already approved branded drugs in terms of safety, efficacy, structure, immunogenicity profile, etc. In Europe, biosimilars are manufactured, developed and approved according to the stringent laws laid down by the European Medicines Agency (EMA). A significant rise in the ageing population has led to the prevalence of various chronic diseases in the region. For instance, according to a report by WHO, cancer has emerged as the second major cause of death and morbidity in Europe with more than 3.7 million new cases and 1.9 million deaths each year. As a result of this, cancer supportive biosimilars, such as Filgrastim and Erythropoietin, are widely being recommended by doctors in the region. Moreover, the biosimilar manufacturers in the region are continuously developing new products which are projected to help in increasing the availability of biological treatments for the patients.

4. Report Description and Highlights Report Description • European Biosimilar Market Trends: • The growing awareness among the patients in Europe regarding the efficacy and safety of biosimilars as compared to patented drugs has created a positive outlook for the market growth. Apart from this, as patients have limited access to biologics owing to their relatively high cost, there has been a huge demand for the lower priced biosimilars. This has further helped in lowering the cost of treatment of chronic diseases such as diabetes, cancer, CVDs, autoimmune diseases, rheumatoid arthritis, kidney failure, growth hormone deficiency, infectious diseases, etc. Moreover, the EMA and the European Commission are working towards improving the understanding of biosimilar use across the European Union (EU). In line with this, they have published information material on biosimilar medicines which offers healthcare professionals with comprehensive information about their regulations and usage. As a result of these factors, the market is projected to exceed a value of US$ 9,173 Million by 2023, exhibiting at a CAGR of 29% during 2017-2023. • European Biosimilar Market Summary: • Based on molecule, infliximab dominates the market, accounting for the highest sales. Other major molecules include insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab and follitropin alfa.

5. Report Description and Highlights Report Description • Read more here: http://bit.ly/2yHrbqR • On the basis of manufacturing type, the market has been segmented into in-house and contract manufacturing. Currently, in-house manufacturing represents the largest segment, holding the majority of the overall market share. • Based on indication, autoimmune diseases are the biggest indication for biosimilars. Other major indications include oncology, autoimmune diseases, blood disorders, growth deficiency and diabetes. • Region-wise, Italy enjoys the leading position in the European biosimilar market. Cost containment measures in the country represent the major driver catalyzing the uptake of biosimilars in the country. Other major markets are Germany, the United Kingdom, France, and Spain. • The competitive landscape of the biosimilar market in Europe has also been analyzed with some of the key players being Novartis, Pfizer, Teva, Ratiopharm, Celltrion, Merck Sharp & Dohme, Samsung Bioepis, Eli Lilly, Accord Healthcare Ltd., Mylan, Boehringer Ingelheim, Hexal Ag, Apotex, StadaArzneimittel Ag, and Amgen. • Want more information about this market? Request a free report sample: • https://www.imarcgroup.com/request?type=report&id=1023&flag=B

6. Report Description and Highlights Browse More Related Reports:  Biosimilar Market: http://bit.ly/2RPDZ7n Intrauterine Devices Market:  http://bit.ly/2RF4iwY

7. Report Description and Highlights Report Description © 2017 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

8. Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: • TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com